Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

NCT07493161 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Ph+ ALL

Interventions

DRUG: Olverembatinib
DRUG: Venetoclax
DRUG: Blinatumomab
DRUG: Chemotherapy Backbone Regimens
OTHER: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China